Cipla – Global Pharmaceutical Leader
Cipla
Cipla Limited is an Indian pharmaceutical company founded in 1935 in Bombay (now Mumbai) by Khwaja Abdul Hamied as Chemical, Industrial & Pharmaceutical Laboratories; the short name Cipla became official in 1984. It is headquartered in Mumbai, and its shares are listed on the NSE and BSE and included in the NIFTY 50 index.
The company makes generic and branded medicines for respiratory diseases — one of its main areas — as well as HIV, cancer, cardiovascular and other chronic conditions.
Cipla is known for its role in access to HIV treatment. In February 2001 it offered a triple antiretroviral combination for less than one dollar per patient per day, many times cheaper than therapy with the original medicines, making treatment affordable for government programmes and humanitarian organisations in Africa.
Cipla manufactures at its own plants in India and abroad and operates in more than 80 countries, with major subsidiaries in the United States and South Africa, among others.
Unifarm carries Cipla medicines: Tofajak (tofacitinib) tablets and ointment, Osteofos 70 (alendronate sodium), Bosentas (bosentan), Temoside (temozolomide), Erlocip (erlotinib), Soranib (sorafenib), Xbira (abiraterone), Viraday (efavirenz + emtricitabine + tenofovir) and more — see the full list below.